Christophe Ravoet

Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients

P. Wijermans, Michael Lübbert, G. Verhoef et al. · Journal of Clinical Oncology · 2000 · 570 citations

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

Sophie Park, Sophie Grabar, Charikleia Kelaïdi et al. · Blood · 2007 · 328 citations · Full text

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

Michael Lübbert, Pierre W. Wijermans, Regina Kunzmann et al. · British Journal of Haematology · 2001 · 225 citations

Cytogenetics, Epigenetic Change, Genetics +17

Genes encoding tumor-specific antigens are expressed in human myeloma cells.

Nicolas van Baren, F. Brasseur, D. Godelaine et al. · PubMed · 1999 · 196 citations

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

Lionel Adès, Simone Boehrer, Thomas Prébet et al. · Blood · 2008 · 150 citations · Full text